Ivo Tremont Lukats, MD
Neurology · Orlando, FLNPI 1336185420
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,600 of the $4,890 with a category attached, or 73.6%. Novocure Inc. accounts for 88.9% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $3,759 and has fallen 88.8% since, to $422 in 2025.
Across 29 payments — averaging $168.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$4K
- Telix Pharmaceuticals$243
- SK Life Science, Inc.$178
- Pfizer$121
Across 44 payments — averaging $3108.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novocure GmbH$117K
- Incyte Corporation$17K
- Novocure Inc.$3K
What the payments were for
- Speaking & faculty fees$3,60074%
- Travel & lodging$1593%
- Food & beverage$1,13223%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 14 | $4,349 |
| Telix Pharmaceuticals | 2 | $243 |
| SK Life Science, Inc. | 8 | $178 |
| Pfizer | 5 | $121 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Oncology$3,759
- ILLUCCIX$310
- Optune$138
- Optune Gio$133
How this compares
$4,890 in reported general payments places this provider in the 60th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lacosamide | 32 | $4,687 |
| Levetiracetam | 33 | $1,725 |
| Memantine Hcl | 67 | $1,047 |
| Levetiracetam ErLevetiracetam | 42 | $648 |
| Pregabalin | 12 | $616 |
| Dexamethasone | 47 | $616 |
| Lamotrigine | 40 | $409 |
| Clonazepam | 14 | $395 |
| Gabapentin | 17 | $261 |
| Ondansetron Hcl | 54 | $251 |
| Mirtazapine | 16 | $206 |
| Olanzapine | 14 | $204 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 15 | $127 |
| Hydrocortisone | 11 | $124 |
| Topiramate | 12 | $99 |
Paid to pharmacies, not to this prescriber.
Other neurology in Orlando
- Ramon Rodriguez CruzOrlando$1M
- Mark KlafterOrlando$247K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.